


LONG-ACTING FORMS OF HIV PREVENTION

For some people, long-acting forms of HIV prevention may be more desirable than a daily pill.


HIV prevention today — and in the future.

Taking an oral dose of the medication Truvada **once a day, every day** can prevent HIV infection.



NIAID-funded researchers are developing and testing **alternative HIV prevention products** that could be inserted, injected, infused or implanted from

Monthly



ONCE A MONTH...

...TO ONCE A YEAR


Yearly



in people who commit to use the products on an ongoing basis.


NIAID is funding research on 4 types of long-acting HIV prevention.

INTRAVAGINAL RING (IVR)




Polymer ring inserted into the vagina releases antiretroviral drug over time.

IMPLANT




Device implanted in the body releases antiretroviral drug over time.

INJECTABLE



Long-acting antiretroviral drug is injected into the body.

ANTIBODY




Antibody is infused or injected into the body.

How many products are under investigation?




dapivirine IVR (MTN 034/REACH clinical trials)
tenofovir IVR (CONRAD)
Truvada IVR (Oak Crest Institute of Science)



cabotegravir (SLAP-HIV project)
dolutegravir (University of North Carolina)
tenofovir alafenamide (Oak Crest Institute of Science)
tenofovir alafenamide & emtricitabine (Houston Methodist Research Institute)




cabotegravir (HPTN 077, 083 & 084 clinical trials)



CAP256V2LS (NIAID VRC & CAPRISA)
N6LS (VRC 609 clinical trial)
PGT121.414.LS (NIAID)
Sanofi trispecific antibody (NIAID VRC & Sanofi)
VRC01 (AMP Studies, HVTN 116 & IMPAACT P1112 clinical trials)
VRC01LS (HVTN 116 & IMPAACT P1112 clinical trials)
VRC07-523LS (VRC 610, HVTN 127/HPTN 087 & IMPAACT P1112 clinical trials)

At what stage is this research?



For more on the latest advances in HIV prevention research, visit: